Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patients

INTERVENTION: URLC10,TTK,KOC1,VEGFR1,VEGFR2‐derived peptide vaccine CONDITION: chemotherapy‐resistance unresectable esophageal cancer PRIMARY OUTCOME: safety SECONDARY OUTCOME: immunological responce; tumor regression; survival time INCLUSION CRITERIA: 1)pathologicaly diagnosed esophagal squamous cell carcinoma 2)unresectable and refractory for standard chemotherapy 3)Performance status(ECOG) 0,1,2 4)obtains lesionthat can be evaluated by RECIST 5)more than 4 weeks after prior therapy 6)WBC >=2000, <=15000 Platelet>=50000 Total Bilirubin<=3.3 Creatinine<=2.2 7)HLA‐A*24:02 8)obtains writen informed consent